Hyperthyroidism: What the generalist should know by Ross, Ian Louis & Levitt, Naomi S
Thyrotoxicosis is one of the more com-
mon endocrine disorders and most cases
result from hyperactivity of the thyroid
gland (hyperthyroidism) (Table I).
THYROTOXICOSIS
Younger patients with thyrotoxicosis of
any cause may present with palpitations,
anxiety, easy fatigability, psychomotor
activity, diarrhoea, excessive sweating,
heat intolerance, preference for cold,
amenorrhoea, and marked weight loss
without appetite loss.
However, there is a small group of hyper-
thyroid patients who describe weight gain
at presentation as a result of increased
appetite exceeding the increase in basal
metabolic rate induced by excess thyroid
hormones.
The clinical features of tachycardia,
tremor, sweating and lid lag associated
with thyrotoxicosis suggest catecholamine
excess.Yet circulating levels of cate-
cholamines are normal and the increased
sympathetic activity is accounted for by
an increased number of beta-receptors.
Thyroid enlargement and muscle weak-
ness may occur.
Elderly patients commonly present with
cardiovascular involvement such as atrial
fibrillation and develop palpitations and
dyspnoea on exertion. Older patients may
also present with ‘apathetic’ hyperthy-
roidism.
Laboratory findings
Primary hyperthyroidism is confirmed by
a suppressed thyroid-stimulating hormone
(TSH), with an elevated free T4 or free T3
in the case of a normal free T4.
As the cause of hyperthyroidism may not
be evident clinically, further investigation
is frequently required, using a technetium
thyroid uptake scan.
Therapy
The specific therapeutic modality for
hyperthyroidism is dependent upon the
underlying cause. Options include
antithyroid drug therapy, surgery and
radioactive iodine. However, treatment
varies according to the cause of hyperthy-
roidism.
Beta-blockade is an important adjunct to
therapy and has greatest value in counter-
acting the sympathetic overactivity. In
asthmatics calcium channel blockers may
be used as an alternative to beta-blockers.
Calcium channel blockers may successful-
ly block chronotropy but will fail to coun-
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Hyperthyroidism is a relatively common problem,
particularly among women. Its management can
be complex and requires a good understanding
of the underlying pathology.
Common
• Graves’ disease
• Toxic multinodular goitre







• Syndrome of inappropriate TSH
secretion
Table I. Causes of 
hyperthyroidism
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teract the excess sympathetic over-
activity  (Table II).
GRAVES’ DISEASE
Graves’ disease is the most com-
mon form of thyrotoxicosis. It is
an autoimmune condition of
unknown aetiology and occurs
more commonly in women. There
is a strong familial predisposition
as 15% of patients have a close rel-
ative with Graves’ disease and cir-
culating thyroid antibodies are
found in 50% of relatives.
Pathogenesis
Graves’ disease results from the
sensitisation of  T lymphocytes to
antigens within the thyroid. The
subsequent stimulation of B lym-
phocytes results in the synthesis of
antibodies to the TSH receptor on
the thyroid cell membrane. These
antibodies have the ability to pro-
mote thyroid cell growth and func-
tion (TSH receptor-stimulating
antibodies) and their presence is
positively correlated with active
disease and relapse. The sensitised
lymphocytes release cytokines
which cause inflammation of the
orbital fibroblasts and orbital mus-
cles, resulting in swollen orbital
muscles and proptosis.
Predisposing factors for the
development of Graves’ 
disease
In the majority of cases no cause
can be identified, but certain fac-
tors have been shown to incite the
development of Graves’ disease.
These include the postpartum
period where there is a resurgence
of immune-mediated conditions,
iodide exposure to patients from
iodide-deficient areas, lithium ther-




There are a number of clinical fea-
tures which are so specific to
Graves’ disease that diagnosis can
be certain once hyperthyroidism is
confirmed biochemically. These
include: a diffusely enlarged thy-
roid gland with an obvious bruit,
Graves’ ophthalmopathy and thy-
roid dermopathy which consists of
thickening of the skin, particularly
the lower tibia, due to the accumu-
lation of glycosaminoglycans (Fig. 1).
Thyroid dermopathy is relatively
rare, with an incidence of 2 - 3%
of patients with Graves’ disease. It
is usually associated with ophthal-
mopathy. Graves’ ophthalmopathy
is most commonly bilateral, but
may be unilateral (Table III).
Where unilateral, the diagnosis
may be made once there has been
confident exclusion of a unilateral
mass lesion behind the proptosed
eye (Fig. 2).
A relatively common additional
finding is onycholysis where there
is separation of the fingernails from
their beds. It is easy to recognise
because of the accumulation of
grime, despite the best intention to
keep the nails clean. This on its
own is not diagnostic of Graves’
disease.
Laboratory findings 
A suppressed TSH and a normal
T4 mandates the checking of T3
because it may indicate early
Graves’ disease. In the absence of
any of the characteristic signs of
Graves’ disease a thyroid uptake
scan is required for definitive diag-
nosis. An elevated, diffuse uptake
on scan is diagnostic of Graves’
disease.
Therapeutic options for 
treatment
Options for therapy for Graves’
disease include antithyroid drug
therapy, surgery and radioactive
iodine.
Antithyroid drug therapy
This is most useful in younger
patients. Either carbimazole or
propylthiouracil may be used. The
Graves’ disease Antithyroid drugs, radioactive iodine, surgery
Toxic multinodular Radioactive iodine or surgery
gland*
Toxic adenoma* Radioactive iodine or surgery
Thyroiditis Beta-blocker and in cases of painful subacute 
thyroiditis aspirin or glucocorticoids, 
depending on severity
* The primary care physician may wish to stabilise the patient on antithyroid drugs initially, while
arranging definitive therapy.
Table II. Specific options for management of 
various causes of hyperthyroidism
Fig. 1. Severe thyroid dermopathy.
Fig. 2. Unilateral Graves’ 
ophthalmopathy.
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normal starting doses of carbima-
zole are 30 - 45 mg per day and of
propylthiouracil 300 - 450 mg per
day. The therapy is continued for
12 - 18 months, with drug dosage
titration dependent upon the levels
of thyroid hormone.
Ideally TSH and T4 should be
monitored at approximately 6-
weekly intervals.
Sustained remission of Graves’ dis-
ease can be predicted by the thy-
roid gland returning to normal
size, if the TSH receptor-stimulat-
ing antibody is no longer
detectable in serum (Table V), or if
the disease can be controlled with
a low dose of antithyroid drugs.
A rash may occur in 5% of patients
taking antithyroid drugs and can
be managed with antihistamines.
Unless the rash is severe, it is not
an indication for discontinuing the
antithyroid drugs. Agranulocytosis
is a serious, potentially life-threat-
ening complication which occurs
less frequently, in approximately
0.5% of patients on antithyroid
treatment. Agranulocytosis is often
heralded by a sore throat and fever
but may be asymptomatic. This
complication demands the immedi-
ate cessation of antithyroid therapy.
Other rare complications of
antithyroid drugs include cholesta-
tic jaundice, angioneurotic oedema
and hepatocellular toxicity.
Surgery
Surgery for Graves’ disease is con-
sidered when the thyroid gland is
very large. In these cases a subto-
tal thyroidectomy is performed.
The patient should be rendered
euthyroid with antithyroid drugs
before surgery. Potassium iodide is
often administered before surgery
to reduce the vascularity of the
gland. Many centres in South
Africa and in the UK preferentially
treat Graves’ disease with medical
therapy, at least until there is fail-
ure of antithyroid drugs.
Radioactive iodine
In the USA radioactive iodine is
the preferred initial management in
most patients over the age of 21
years. Usually the gland will shrink
after administration of radioactive
iodine. Patients with coexistent
heart disease or severe thyrotoxico-
sis should preferably be treated
with antithyroid drugs initially to
achieve euthyroidism, and when
euthyroid should be treated with
radioactive iodine. The antithyroid
drugs should be discontinued 5 - 7
days prior to administering
radioactive iodine and recom-
menced 3 days after the radioactive
iodine.
Ultimately hypothyroidism devel-
ops in 80% or more Graves’ dis-
ease patients treated with radioac-
tive iodine. Radioactive iodine
may initially induce radiation thy-
rotoxicosis, with worsening of the
thyrotoxicosis. This complication
is fortunately rare and can be min-
imised by treating patients with
very high levels of T4 with antithy-
roid drugs before therapy with
radioactive iodine. Radioactive
iodine may worsen Graves’ oph-
thalmopathy. Consequently, any
patient with ophthalmopathy
requires careful evaluation and
consideration for steroid cover if




Typically thyrotoxicosis arises in
older patients who have had a
longstanding multinodular goitre.
Pathogenesis
Thyrotoxicosis results from the
development of functional autono-
my of some of the nodules over
time. The precise mechanism of
these changes is not known.
However in some individuals thy-
rotoxicosis may be precipitated
after excess iodine uptake, for
example radio contrast material.
• Pain, painful oppressive feeling behind globe
• Pain on attempted up, side or down gaze
• Redness, redness of conjunctiva
• Swelling or chemosis of conjunctiva
• Oedema of eyelids
• Caruncle swelling
• Proptosis*
• Impaired function, decrease in visual acuity/one or more lines
• Decrease of eye movements in any direction ≥ 50*
*Increasing proptosis or decreasing eye movements are followed to determine the progression of
Graves’ eye disease.
Table III. Graves’ disease eye signs
An example of dose titration
A patient whose T4 is 70 pmol/l
(normal 11 - 24 pmol/l) would
require in the order of 40 mg
carbimazole. After 6 weeks of
continued therapy the patient
with a reasonably good response
may have reached a T4 of 30
pmol/l (Table IV). At this stage
one is obliged to reduce the
dose to 20 mg even though the
patient remains thyrotoxic.
Premature withdrawal of car-
bimazole will result in a higher
relapse rate.
• Small thyroid gland
• Only mildly elevated T4 levels
• Female gender
• Age less than 50 years
Table IV. Predictors of a
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Clinical features
The extent of overproduction of
thyroid hormone in a toxic multi-
nodular goitre is usually less dra-
matic than in Graves’ disease. It
usually occurs in patients over the
age of 50 years. Cardiac manifes-
tations of atrial fibrillation and
tachycardia with or without cardiac
failure tend to predominate. The
nervous system manifestations are
less apparent. As the gland may
enlarge quite substantially, obstruc-
tive symptoms may result.
Laboratory investigations
In any patient with a multinodular
goitre, it is essential to determine
whether there is coexisting thyro-
toxicosis. The laboratory findings
consistent with this diagnosis are a
suppressed TSH, often strikingly
high T3 and an increased T4.
Patchy uptake on technetium or
radioiodine uptake scans, normal
or elevated in quantity, suggests a
toxic multinodular goiter.
Therapy
The treatment of choice for this
condition is radioactive iodine, but
surgery may be employed for larger
glands. As many patients with this
disorder are elderly and have
underlying heart disease, medical
therapy should be initiated to
achieve euthyroidism before
administration of radioactive
iodine. The antithyroid therapy is
temporarily withdrawn 5 days
before the radioactive iodine and
resumed 3 days after the adminis-
tration of radioactive iodine.
TOXIC ADENOMA
A toxic adenoma, also referred to
as Plummer’s disease, is a less
common cause of hyperthyroidism.
Pathogenesis
Pathogenically, this condition
results from an adenoma which
progressively gains autonomy and
elaborates excessive amounts of
thyroid hormone. A substantial
proportion are caused by gain of
function mutations in the TSH
receptor gene. The progression of
this condition can sometimes be
visualised on thyroid scan. It com-
mences as a hot nodule which
slowly increases in size and gradu-
ally suppresses the other thyroid
lobe. These adenomas are almost
never malignant.
Clinical features
Toxic adenomas occur in younger
patients, with a peak incidence in
the 30 - 40-year age group. The
nodule is felt as a smooth, well-
defined round mass that moves on
swallowing.Usually there is a histo-
ry of a slow-growing lump in the
neck, but thyrotoxicosis results
when these lesions exceed 2.5 - 3.0
cm. These adenomas may undergo
central necrosis and haemorrhage.
Once again the peripheral manifes-
tations are milder than in Graves’
disease.
Laboratory tests
Once thyrotoxicosis supervenes the
TSH is suppressed, the T4 levels
are occasionally normal, while only
the T3 is increased. Toxic adenoma
is a frequent, known cause of T3
toxicosis, although the usual sce-
nario is for both T3 and T4 to be
elevated.
Therapy
Smaller nodules are best managed
by radioactive iodine therapy, while
larger ones are best managed by
surgical excision. Euthyroidism
must be instituted medically before
surgery.
THYROID CRISIS
A thyroid storm or thyroid crisis,
as it is preferentially known, is a
clinical syndrome where there is
marked exaggeration of the thyro-
toxicosis. It is an uncommon but
serious complication. The clinical
settings predisposing to the devel-
opment of a thyrotoxic crisis or
thyroid storm are shown in Table
VI.
Pathogenesis
Although the pathogenesis of a
thyroid crisis is uncertain, interest-
ingly thyroid hormone levels are
not higher than in patients with
thyrotoxicosis without a thyroid
storm. The fundamental difference
is that the number of binding sites
for catecholamines increases, so
that the heart and nerves have
increased sensitivity to cate-
cholamines. There is also simulta-
neous decreased binding of T3 and
T4 to thyroid binding globulin,
resulting in increased free T3 and
free T4.
Clinical features 
Noticeably the hyperpyrexia that
occurs with a thyroid storm is out
of keeping with the other clinical
features and may be accompanied







• Severe drug reaction
Table VI. Precipitants of
thyrotoxic crisis 
(thyroid storm)
• If the thyroid gland returns to normal size
• Disease can be controlled with a relatively low dose of antithyroid
drugs
• If the TSH receptor Ab (stim) is no longer detectable in the serum 
Table V. Predictors of sustained remission in Graves’
disease
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by profuse sweating. Marked
tachycardia may be associated with
congestive cardiac failure frequent-
ly manifesting with pulmonary
oedema. At the outset of the crisis
tremor and restlessness are charac-
teristic, but as this disorder pro-
gresses apathy and coma may
supervene. A late feature is the
finding of hypotension. If the thy-
roid crisis is not recognised and
not appropriately managed, it is
invariably fatal.
Therapy
Therapy is aimed at correcting the
severe thyrotoxicosis and the pre-
cipitating illness. Large doses of
antithyroid drugs are given by
mouth or nasogastric tube.
Potassium iodide is then adminis-
tered. In theory, it is desirable to
administer antithyroid drugs before
initiating potassium iodide therapy
to prevent the release of preformed
thyroid hormone. Large doses of
dexamethasone may also be used
as adjunctive therapy as it has the
advantage of inhibiting the forma-
tion of  T3 from T4. A beta-blocker
should be given in the absence of
cardiac dysfunction or asthma to
reduce the sympathetic effects of a
thyroid crisis, and salicylates must
be avoided. Addressing the thyro-
toxicosis alone is insufficient and
aggressive management of the
underlying medical condition is
warranted.
THYROIDITIS
Thyroiditis represents a group of
heterogeneous disorders of which a
common feature is an inflammato-
ry infiltrate. Subacute or chronic
thyroiditis are two groups of condi-
tions that may give rise to hyper-
thyroidism. These patients present
with acute release of preformed
thyroid hormone-producing symp-
toms of mild to severe thyrotoxico-
sis. These illnesses can be distin-
guished from other causes of thyro-
toxicosis by the markedly reduced
radioactive iodine uptake on thy-
roid scan. In addition, the natural
tendency is for the symptoms to
subside spontaneously over a peri-
od of weeks or months.
Subacute thyroiditis (De
Quervain’s thyroiditis)
This is an acute inflammatory dis-
order of the thyroid gland caused
by a viral infection, and a promi-
nent symptom is one of pain of the
anterior part of the neck.
Importantly, this occurs in the
absence of erythema. Thyrotoxic
features may be present and are
usually accompanied by laboratory
values consistent with thyrotoxico-
sis. The erythrocyte sedimentation
rate is frequently greater than 100
mm per hour. For the most part
only symptomatic treatment is nec-
essary and a short course of aspirin
or glucocorticoids may be neces-
sary to reduce inflammation.
Usually this results in spontaneous
resolution of inflammation and
restoration of euthyroidism. A vari-
ation of subacute painful thyroidi-
tis is a painless form without ele-
vated inflammatory markers. This
occurs commonly in the postpar-
tum period.
Chronic thyroiditis
Although this condition may mani-
fest with hyperthyroidism, the vast
majority of cases progress to
hypothyroidism due to the relent-
less destruction of the thyroid
gland. As this disease entity is asso-
ciated with lymphocytic infiltration
and high levels of circulating anti-
bodies, it may coexist with other
autoimmune conditions. These
include type 1 diabetes, hypoad-
renalism, premature ovarian failure
and pernicious anaemia, among
others. In keeping with its autoim-
mune character high titres of thy-
roid antibodies are helpful in
clinching the diagnosis, but low
titres of these antibodies do not
exclude this disease especially in
younger patients.
RARE FORMS OF THYRO-
TOXICOSIS (TABLE I)
Thyrotoxicosis factitia
Thyrotoxicosis factitia is a psy-
choneurotic condition that leads an
individual to ingest thyroxine for
the purpose of weight loss. The
person usually has some connec-
tion with the field of medicine and
as a result has no difficulty in
procuring thyroxine. The features
of thyrotoxicosis occur without
goitre or eye signs. The radioactive
iodine uptake or technetium scan
is negligible and formal psy-
chotherapy may be indicated.
Struma ovarii
A struma ovarii is a form of
ectopic source of thyroid hormone
arising from a teratoma of an
ovary. Thyrotoxicosis occurs in the
absence of a goitre. There is
absence of uptake in the neck on
thyroid scan, but the body scan
reveals uptake in the pelvis.
Follicular carcinoma
Follicular carcinoma rarely may
secrete active thyroid hormone.
There are only a few case reports
of patients presenting with hyper-
thyroidism as a consequence of
metastatic carcinoma. In some
instances the metastatic deposits
may concentrate radioactive iodine.
This ability has given rise to the
treatment of a follicular thyroid
carcinoma with high doses of
radioactive iodine.
Trophoblastic disease
Hydatidiform moles and choriocar-
cinomas produce chorionic
gonadotropin which has intrinsic
TSH-like activity. This results in
suppressed TSH levels and occa-
sionally overt thyrotoxicosis
accompanied by elevated T4 and
possibly T3 concentrations. The
thyrotoxicosis is ameliorated by
removal of the mole or treatment
of the choriocarcinoma.
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‘Hamburger thyrotoxicosis’
‘Hamburger thyrotoxicosis’ result-
ed from the practice of using neck
muscles containing beef thyroid
tissue to make hamburgers.
Currently this practice is illegal.
The syndrome of inappropriate
TSH
The inappropriate TSH syndrome
(high TSH, high T4, high T3) may
give rise to thyrotoxicosis by way of
the rare entity of a TSH-secreting
tumour. This is usually a
macroadenoma of the pituitary.
The inappropriate TSH syndrome
may also be the result of thyroid
hormone resistance.
CONCLUSION
Thyrotoxicosis is a frequently
encountered clinical condition and
its presentation may differ depend-
ing on the age of the patient.
Thyrotoxicosis is most effectively
managed by determining the
underlying cause, followed by insti-
tuting the most appropriate mode
of therapy. Graves’ disease is the
most common form of thyrotoxico-
sis. It is recognised by one of the
following clinical features, namely
ophthalmopathy, a bruit over the
thyroid gland or pretibial myxoede-
ma. Antithyroid therapy should be
initiated by the primary care physi-
cian, except where the diagnosis is
doubtful and the presentation is
atypical or complicated.
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SINGLE SUTURE
Rich and dark 
There is potentially good news for lovers of plain chocolate. Consumption of plain, dark chocolate
resulted in an increase in both the total antioxidant capacity of plasma and the plasma content of the
dietary flavonoid 
epicatechin (which is thought to promote cardiovascular health). Both effects were greatly reduced
when the chocolate was consumed with milk, or milk was incorporated as milk chocolate.
(Serafini M, et al. Nature 2003; 424: 1013.) 
SINGLE SUTURE
Out of Attica
In Greece, the Attica study found that a high proportion of the population is unaware of having high
blood pressure, and blood pressure isn’t checked regularly in Greece. Prevalence of hypertension in
men was 38% and 24% in women. However, there is a general belief that the so-called Mediterranean
diet is helping to prevent hypertension among those predisposed to the condition. But, these results
may suggest another reason for the apparently low rate of cardiovascular disease among
Mediterranean people — they are simply not being diagnosed.
(Panagiotakos DB, et al. J Hypertens 2003; 21: 1483-1489.)
